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Abstract 
The GloPID-R (Global Research Collaboration for Infectious Disease Preparedness) Chikungunya 
(CHIKV), O’nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group is investigating the natural 
history, epidemiology and medical management of infection by these viruses, to identify knowledge 
gaps and to propose recommendations for direct future investigations and rectification measures. 
Here, we present the first report dedicated to diagnostic aspects of CHIKV, ONNV and MAYV. 
Regarding diagnosis of the disease at the acute phase, molecular assays previously described for the 
three viruses require further evaluation, standardized protocols and the availability of international 
standards representing the genetic diversity of the viruses. Detection of specific IgM would benefit 
from further investigations to clarify the extent of cross-reactivity among the three viruses, the 
sensitivity of the assays, and the possible interfering role of cryoglobulinaemia. Implementation of 
reference panels and external quality assessments for both molecular and serological assays is 
necessary. Regarding sero-epidemiological studies, there is no reported high- throughput assay that 
can distinguish among these different viruses in areas of potential co-circulation. New specific tools 
and/or improved standardized protocols are needed to enable large-scale epidemiological studies of 
public health relevance to be performed. Considering the high risk of future CHIKV, MAYV and ONNV 
outbreaks, the Working Group recommends that a major investigation should be initiated to fill the 
existing diagnostic gaps. 
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1. Introduction 
The GloPID-R (Global Research Collaboration for Infectious Disease Preparedness) Chikungunya 
(CHIKV), O’nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group presents a report 
dedicated to diagnostic aspects of these pathogens. Overlapping clinical presentations, wide 
geographic spread and the possible selection of viruses capable of transmission by new vectors 
highlight the need for laboratory diagnostic support to unambiguously identify etiological agents in 
cases of undefined febrile illness with arthralgia and/or rash. This is important to ensure an early 
detection of cases and to support a clinical and public health response. 
 
In order to assess the currently available molecular and serological tools to diagnose infections by 
CHIKV, ONNV and MAYV, the experts of the GloPID-R have performed a systematic review of English 
literature on the diagnostic aspects of the three viruses present on PubMed until September 2018. 
Diagnosis of the diseases at the acute phase mostly relies on molecular detection of the virus 
genomes: we discussed about kinetics of viral loads and biological sampling, choice of molecular tool, 
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available in-house and commercial molecular tests, international standards and external quality 
assessments organized to investigate laboratories’ capability for viral detection. Alternatively, 
diagnosis can be provided by the detection of specific antibodies, so we focused on kinetics of 
immune response, choice of serological tool, commercially available tests, international standards 
and external quality assessments; moreover, cryoglobulinaemia and cross-reactivity, that can 
interfere with the correct identification of antibodies, were discussed, as well as cross-protection and 
cross-neutralization among the three pathogens. 
Viral isolation by culture has not been taken into account because its turnaround time hardly fits with 
the need for an early diagnosis. Although in some cases (i.e. 2005-2006 CHIKV outbreak in Mauritius 
(1)) virus isolation has been performed for laboratory diagnosis with good sensitivity, providing 
results 2-3 days after inoculation, this diagnostic modality is being replaced by molecular techniques 
including RT-PCR, that are faster, more sensitive and safer and require less laboratory infrastructure. 
However, virus isolation remains a crucial tool in reference laboratories to characterize circulating 
strains to support control and development of diagnostic tools.  
In this report, the experts identified knowledge gaps and provided adapted recommendations.  The 
objective was to suggest relevant research priorities in the field, in order to improve individual 
patient care and outbreak management. 
2. Background 
 
2.1. Epidemiology 
At least 5 million cases over the last 15 years (2) are reason enough to recognize Chikungunya virus 
(CHIKV) as an emerging global health threat. Data from the two largest CHIKV epidemics so far 
highlight the ability of the virus to spread rapidly over great distances and in multiple locations. 
During the 2004-2006 outbreak in the Indian Ocean region, attack rates peaked at 63% in the 
Comoro Islands; La Réunion Island registered 47,000 cases in a single week (January 30th to February 
5th, 2006), with almost 40% of the population estimated to have experienced CHIKV disease; India 
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recorded at least 1.4 million cases at the end of 2006. In late 2013, CHIKV emerged in the New 
World, when in the island of Saint Martin CHIKV infection was identified in patients with no history of 
travel abroad. The virus spread to 45 countries and territories in North, Central, and South America 
and the Caribbean Islands; by the end of 2017, 544 deaths directly or indirectly related to the 
outbreak in the Americas were recorded, together with 2.5 million cases of infections. Transmission 
is ongoing in some locations (3).  
CHIKV is a mosquito-transmitted alphavirus belonging to the family Togaviridae (4). The two major 
vectors of the disease are Aedes (Stegomyia) aegypti and Ae. (Steg.) albopictus (5), the latter 
identified during the 2004-2006 outbreak in the Indian Ocean, when the first in a series of  adaptive 
mutations in the glycoprotein genes of the virus increased  its replication in this specific vector (6,7). 
Two transmission cycles have been described. A sylvatic cycle maintains CHIKV in Africa involving 
forest-dwelling mosquito species (such as Ae. africanus and Ae. furcifer–taylori) and mainly 
nonhuman primates (8); in this context, humans are incidental hosts and become infected when they 
enter the forest or when infected vectors invade adjacent villages from the forest. Several wild 
animal species, especially nonhuman primates, have been investigated as possible virus reservoirs 
sustaining virus circulation in the environment in the absence of human cases (9). CHIKV can also be 
maintained through an urban human-mosquito-human transmission cycle, that involves Ae. aegypti 
and Ae. Albopictus mosquitoes; this cycle has been observed in the Americas, Indian Ocean, Asia and, 
more recently, Europe. In this urban context, humans can serve as reservoir and amplification hosts 
(10).  
Several factors contribute to massive CHIKV circulation: e.g. high mosquito densities, including 
following recent invasions of the main urban vectors, Aedes species; vectorial capacity in transmitting 
the virus (high susceptibility to CHIKV as well as preference for feeding on human beings); high 
viremia level in infected humans; large population of susceptible individuals exposed for the first 
time in several countries; increasing travel from countries with ongoing circulation that enables 
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importation of viremic cases into virus-naïve regions, allowing the virus to extend its geographic 
distribution if conditions for local transmission are present.  
CHIKV forms, with seven other alphaviruses, the Semliki Forest serocomplex, in which E1 envelope 
glycoprotein gene amino acid sequence divergence is below 40% (11). Among this serocomplex, 
viruses from the species Mayaro virus (MAYV) and O’nyong-nyong virus (ONNV) are of particular 
interest because they have potential to emerge in the human population (12,13).  
ONNV is transmitted by anopheline mosquitoes; it is probably maintained through an enzootic cycle 
that has not been characterized yet, and humans can serve as amplification hosts during epidemics 
(14). MAYV is transmitted by Haemagogus species mosquitoes in an enzootic cycle in which 
nonhuman primates seem to be the main amplifier vertebrate hosts, with limited spillover to humans 
who frequently enter forest habitats (15).  
CHIKV, ONNV and MAYV are phylogenetically related:  they share some features that make 
differential diagnosis among the three viruses a challenging task. 
 
2.2. Clinical presentation  
Infections by CHIKV, ONNV and MAYV share an apparent similar clinical picture, with a "dengue-like" 
syndrome (10,14,15). This typically includes fever, headache and a papular or maculopapular rash 
during the acute stage, together with a more specifically remarkable incapacitating polyarthralgia, 
which is the hallmark of these so-called "alphavirus arthritogenic diseases". Although disease is 
generally self-limiting, severe joint pain can persist for months or even years in some individuals (16).  
2.3. Co-circulation 
CHIKV impacts human health globally, with local transmission reported in Asia, Africa, Europa, 
Americas, Pacific region and, transiently, in Europe (10,13). MAYV circulation has mostly been limited 
to South America with sporadic outbreaks next to forest environments (17–19). Recently detected 
MAYV infections in Haiti in a patient with no history of travel abroad living in a non-forest area, and 
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in Panama suggest (I) the spread of the virus towards Central America and the Caribbean and (II) a 
possible human-to-human transmission (20,21). ONNV is endemic in sub-Saharan Africa and it has 
been associated with sporadic large-scale epidemics. The first one, in 1959-1962, accounted for more 
than 2 million cases in eastern Africa alone (22); then, after an apparent absence of about 35 years, 
ONNV re-emerged in Uganda in 1996 (23), showing again its potential to cause massive outbreaks. 
Moreover, the actual distribution of ONNV in Africa is likely to be broader. Limited availability of 
diagnostic tools may have led to confusion of ONNV and CHIKV outbreaks (24).  
Co-circulation of CHIKV-MAYV in Southern and Central America and CHIKV-ONNV in the African 
continent,  do not allow to make a reliable diagnosis based on the geographic area where the 
infection is contracted; moreover, the wide circulation of other pathogens causing febrile illness 
(such as dengue virus and malaria-causing Plasmodium species) makes a travel history of the patient 
insufficient to narrow the differential diagnosis (25). 
 
2.4. Transmission vectors 
The three viruses do not share the same main mosquito vectors: CHIKV is primarily transmitted by 
Aedes spp; ONNV is unique among alphaviruses in its adaptation to Anopheles spp; MAYV enzootic 
vectors are mostly Haemagogus spp (26–28). However, experimental evidence that Aedes 
mosquitoes can transmit ONNV and MAYV exists (29–31), with a productive viral replication both in 
vitro and in vivo. As CHIKV has taught us, a single amino-acid change in the virus can result in 
increased vector competence from a mosquito species not normally considered a primary vector 
(32). The adaptation of CHIKV leading to higher competence of Ae. albopictus for virus transmission 
among humans illustrates that virus evolution might drive the involvement of other, more 
anthropophilic mosquito species. 
  
3. Chikungunya virus (CHIKV) 
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3.1. Molecular diagnosis 
 
3.1.1. Kinetics of viral load and dedicated biological sampling 
CHIKV infections are characterised by high viremia levels (range: 104-108 RNA copies/mL (33,34)) 
during the acute phase, which includes the first 3-4 days after illness onset (35,36). This stage is 
followed by a rapid decrease of viremia (37): in 2008, Panning et al. (38) showed that real-time RT-
PCR was 100% positive for all sera collected up to day 4  after illness onset, with sensitivity 
subsequently decreasing to 40% at day 7. Similarly, CHIKV loads have been proved to decrease 
significantly in serum from 5 days after the onset of symptoms onwards (39). Even if some persisting 
cases of viremia have been observed (up to 17 days) (40–42), molecular diagnosis should typically be 
performed within the first 7 days on an acute-phase specimen to confirm CHIKV infection (41,43,44).  
The preferred samples for diagnosis are serum or plasma (34,38,41,44,45), but other clinical samples 
have been evaluated for use in diagnosis.  
 
3.1.1.1. Saliva  
Saliva showed a lower sensitivity compared to blood for CHIKV: it has been observed that for 
confirmed CHIKV cases (by IgM or PCR in blood (46)) presenting during the 1st week after illness 
onset, detection rate in saliva was 58,3% compared to 86,1% in blood samples (44). Accordingly, 
testing saliva can be relevant during the 1st week post-symptoms onset if blood samples are difficult 
or impossible to collect, but is associated with decreased detection rate and lower negative 
predictive value.  
 
3.1.1.2. Semen 
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Interestingly, semen has been found positive for a prolonged period of time after symptom onset (30 
days), providing an expanded window for the molecular diagnosis of a recent infection with CHIKV 
(47). This finding needs to be further investigated, in order to assess the risk of sexual transmission of 
CHIKV and how this risk compares to the recently observed sexual transmission of other mosquito-
borne viruses such as Zika virus (48).  
 
3.1.1.3. Urine 
The same study showed CHIKV RNA 30 days after initial symptoms in urine from a patient with a 
positive semen sample (47). Similarly, viral genomes were present up to day 30 post-infection in the 
urine of infected mice, long after viral clearance from the plasma (49). Recently, a case report 
described a patient with meningoencephalitis and ocular lesions having a positive urine sample 40 
days after illness onset (50). However, Musso et al. (44) did not observe a prolonged window of 
detection of CHIKV in urine, with samples testing positive by PCR only if collected during the first 
week after symptoms onset. For confirmed CHIKV patients presenting during the first 7 days after 
illness onset, the detection rate in the urine was 8.3% compared to 86.1% in blood; after the 1st 
week after symptom onset, it decreased to 0%, with no positive urine samples that could confirm 
serological diagnosis of CHIKV infection (IgM+). Bozza et al observed low viral loads in the urine of 
patients with confirmed CHIKV infection (39). Considering the contradictory results, virus shedding 
kinetics in urine deserve a systematic re-assessment with enough power in the cohort size. 
 
3.1.1.4. Breast milk  
Recently, the presence of CHIKV RNA in breast milk was reported 23 days after the inception of 
symptoms in one patient (51); however, another study could not detect viral RNA in maternal milk in 
8 samples collected during viremia (although plasma samples from the same patients were RT-PCR 
positive) (52).  
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3.1.1.5. Cerebrospinal fluid 
In cases of CHIKV infections with neurological involvement, cerebrospinal fluid (CSF) samples can be 
tested with both serological and virological assays, with several studies describing detection of viral 
RNA in CSF (50,52–57). Case reports suggest that genomes can persist in the CSF for 7-10 days after 
illness onset (57,58), with viral loads in the CSF generally lower than in plasma (52).  
 
3.1.1.6. Other fluids and tissues 
The virus has been detected also in amniotic fluid, brain and liver biopsies, neonatal gastric fluids and 
placenta  (52).  Windows of detection of CHIKV genomes in different samples are presented in Figure 
1. 
 
3.1.2. Choice of test  
Several diagnostic methods are available for viral genome detection. Molecular assays targeting 
nucleic acids are sensitive methods in the early stages of infection, before the rise of antiviral IgM 
antibodies (34). Isothermal amplification methods have been described for CHIKV, i.e. loop-mediated 
isothermal amplification (LAMP) and transcription-mediated amplification (TMA) (59–61). However, 
real-time RT-PCR remains the most frequently used technique for routine diagnosis at the acute 
stage of infection, because of its sensitivity, specificity and ease of performance (43). A positive result 
by real-time RT-PCR is enough to make a reliable diagnosis of CHIKV, ONNV or MAYV in areas where 
virus circulation has been previously documented. However, in case the virus is detected for the first 
time in a new geographic area, it is good practice to confirm a positive result by RT-PCR with a 
different test, to rule out a false-positive result caused by laboratory contamination. Conventional 
RT-PCR is still employed for research purposes (i.e. to identify to which lineage a viral strain belongs 
(20,62,63)) but is considered to be outdated for routine diagnostics.  
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3.1.3. In-house real-time RT-PCR  
Several real-time RT-PCR systems have been published (34,38,64–68). Some of them have been 
evaluated in the External Quality Assessment (EQA) organized in 2014 by Jacobsen et al (69); their 
performances are discussed in the paragraph 3.1.6. An alignment of 50 CHIKV sequences available in 
Genbank representing main lineages was made to assess published in-house developed primer sets; 
GenBank accession numbers and results of this in silico analysis are presented in Table 1. Most PCR 
systems show one or more mismatches with CHIKV strains in different proportion and positions; 
particular attention was given to mismatches concerning the five 3’ terminal nucleotides of a primer, 
because it is generally admitted that a single mutation in these positions can significantly 
compromise detection capability of a primer. The table highlights the fact that a number of available 
PCR systems are expected to detect viruses from the WA lineage less efficiently than viruses from the 
other lineages.  
 
3.1.4. Commercial molecular tests    
Several commercial tests from different companies were identified for CHIKV molecular detection by 
real-time RT-PCR (Supplementary data-Table 1). Some of them are formulated in monoplex format, 
whereas others are multiplex assays targeting dengue virus (DENV) and Zika virus (ZIKV) as well as in 
some cases yellow fever virus (YFV) and usutu virus (USUV). RealStar from Altona Diagnostics 
(Hamburg, Germany) is the only ready-to-use kit for real time RT-PCR evaluated in the literature 
through the comparison with a published real-time RT-PCR protocol (38,70). The target region is 
within the non-structural protein 1 (nsP1) gene and the manufacturer claims that the kit allows 
detection of all three CHIKV genotypes; however, lack of data on primers and probe sequences does 
not allow for an in silico analysis to confirm this information, and only the ECSA genotype was tested 
in the evaluation study. The 95% limit of detection (LOD) of the kit is 3.2 genome copies per reaction 
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using a quantified RNA from CHIKV ECSA strain (71). The evaluation study defined the LOD using two 
different thermocyclers, Lightcycler 2.0 and Lightcycler 480. Using in vitro-transcribed RNA copies of 
a fragment of an ECSA strain, 95% LOD was 5.3 copies per reaction with Lightcycler 2.0 and 3.8 copies 
per reaction with Lightcycler 480. Using a plaque-purified and plaque-quantified CHIKV ECSA strain, 
LOD was 0.51 PFU/mL with Lightcycler 2.0 and 0.34 PFU/mL with Lightcycler 480. High specificity was 
established by the absence of cross-reactivity against a large panel of non-CHIKV alphaviruses 
(including MAYV and ONNV) and non-alphaviruses. The RealStar assay had 100% sensitivity and 
specificity when compared with the previously published real-time RT-PCR of Panning et al. (38), 
which has shown good sensitivity (95%) and specificity (87,5%) values in the context of a multi-
partner External Quality Assessment (69). 
The RealStar kit has been used for testing blood donations prior to transfusion as well as for CHIKV 
diagnosis in patients. The French Blood Agency used it during the 2014 CHIKV Caribbean outbreak for 
individual NAT (nucleic acid testing) screening of blood products as a part of implemented strategy to 
prevent CHIKV transfusion-transmitted infections (TTIs) (72).  
According to the datasheet of the company, the FTD DENV/CHIKV real time PCR kit from Fast-track 
Diagnostics has been evaluated with EQA panels from Quality Control for Molecular Diagnostics 
(QCMD) (73); all samples (19) were detected correctly except one.  
During the 2014 CHIKV outbreak in the Americas, a prototype of real-time CHIKV/DENV target-
capture, transcription-mediated amplification (TC-TMA) assay by Hologic, Inc. (San Diego, CA, USA) 
was used for high-throughput screening of blood products (74) on the Panther system (Hologic, Inc.). 
Tests were conducted during and after the CHIKV epidemic in Puerto Rico in 2014 to detect Asian 
genotype viruses in plasma samples.  The Panther system automates all aspects of NAT-based blood 
screening on a single, integrated platform; it is based on Procleix technology (developed by Hologic 
and Grifols), already adapted for transfusion screening for HIV, HBV and HCV. During the epidemic, 
high sensitivity was evidenced for both individually tested samples and 16-sample minipools, with a 
95% LOD of 9.9 and 158 copies per reaction, respectively. 
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The same TC-TMA assay was used by another group in the same period (2014 CHIKV Caribbean 
epidemic) (61), with a LOD of 8.2 copies/reaction. Positive TMA results were confirmed by PCR, 
microarray and next-generation sequencing (NGS) analysis.  
 
3.1.5. International Standard (IS)  
The first CHIKV RNA World Health Organization (WHO) International Standard (IS) for Nucleic Acid 
Amplification Techniques (NAAT)-Based Assays was accepted in October 2017 and is distributed by 
the Paul Ehrlich Institute (Germany) (75). It has been prepared from strain R91064 of the 
East/South/Central African (ECSA) genotype (Indian Ocean lineage), isolated from a patient returning 
from India to the USA in 2006 (34). The accession number for the Genbank sequence  is KJ941050 
(76). The freeze-dried preparation contains heat-inactivated virus that has been diluted in human 
plasma negative for anti-CHIKV antibodies. This reagent has been assigned a unitage of 2,500,000 
International Units/mL, when reconstituted as recommended in 0.5 mL of sterile nuclease-free 
water. The material has been evaluated in an international collaborative study involving 25 
laboratories performing a wide range of CHIKV NAAT assays (77). 
A CHIKV RNA reference reagent (RR) was produced in 2015 by the CBER/FDA (Center for Biologics for 
Evaluation and Research/US Food and Drug Administration) (78). It is now available from the Office 
of Blood Research and Review, CBER/FDA (79). The reference reagent consists of cell culture-grown, 
heat-inactivated CHIKV diluted in human plasma and frozen. The strain is also the above-mentioned 
R91064. In a collaborative study involving 8 laboratories, the RR showed an estimated overall mean 
of 7.56 log10 detectable units/mL, ranging from 6.2 log10 to 8.6 log10 (80). 
International Standards based on West African and Asian lineages have not been developed. This is 
of specific importance, because Asian lineage of CHIKV has been broadly circulating in Asia, Latin 
America and the Caribbean, and there are still episodes of circulation of the West African lineage of 
CHIKV in Senegal and most probably in neighboring countries (81,82). 
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3.1.6. External Quality Assessment (EQA) 
Four EQAs (Table 2) have been organised to investigate laboratories’ capability for detection of 
CHIKV RNA by molecular tools, three of which were coordinated by the European Network for 
Diagnostics of Imported Viral Diseases (ENIVD) (now EVD-LabNet). 
Donoso-Mantke et al. (83) organized in 2007 a study involving 24 European laboratories to assess 
both molecular and serological diagnostics for CHIKV. Testing a panel by molecular tools, a great 
variability in performances was observed; in particular, 4 of the 20 laboratories that participated 
used assays with low sensitivity and specificity. 
In 2007, Panning et al. (84) organized an international proficiency study with 31 participants from 
Europe, Asia, Africa and South America, who were asked to test the material with any molecular 
assay routinely used for detecting CHIKV in human plasma or with a real-time PCR protocol 
previously distributed by the study coordinator. In total, 17/31 laboratories lacked adequate 
sensitivity; those who used the assay distributed by the consortium showed the highest 
performances in term of sensitivity, proving that ad hoc improvement of molecular diagnostics was 
possible. False-positive results obtained with nested RT-PCR, a technique often affected by risk of 
contamination, confirmed it as obsolete for routine diagnosis. 
In 2014, a third EQA (by Jacobsen et al.) involved 56 international laboratories from Europe, Asia, 
Africa, Middle East, Americas, Caribbean, Oceania (69), allowing for worldwide performance 
evaluation. Conventional in-house RT-PCR tests had the highest rate of correct results, although only 
5 laboratories used it; however, low detection rate was observed for the lowest viral load of the 
dilution series. In-house real-time RT-PCR systems were the most commonly used techniques; in 
particular, systems from Pastorino (68) and Panning (38) were used by 9 and 8 out of 42 labs, 
respectively. As other PCR systems used in the EQAs (by Lanciotti and Edwards, both used by 3 labs 
(34,67)), they showed heterogeneous results with laboratories using the same protocol especially in 
terms of sensitivity, suggesting problems associated with laboratory procedures; specificity and 
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genotyping were more often correctly evaluated. Some commercial real-time RT-PCRs (used by 13 
labs) raised issues for their lack of sensitivity and specificity (with the closely related ONNV 
frequently found positive); however, the identification of these poorly performing kits was not 
provided.  
The most recent EQA was conducted in 2015 by Soh et al. (85) among 24 national-level public health 
laboratories in the Asia Pacific region to assess both CHIKV and DENV diagnostics. The majority of 
them requested receipt of a CHIKV-positive control and/or real-time or conventional RT-PCR 
protocols to develop and validate their capacity for CHIKV diagnosis. High degrees of sensitivity and 
specificity were observed, with 19/20 laboratories (95%) having detected correctly CHIKV; the only 
one that detected CHIKV in a serum-only plasma used a real time RT-PCR protocol.  
3.2. Serological diagnosis   
3.2.1. Kinetics of the immune response 
Virus-specific IgM antibodies appear in the serum within 4-6 days after the onset of illness 
(37,86). Accordingly, IgM may be absent at the initial consultation, at the acute stage of the disease. 
They generally can be detected up to 3-4 months after infection (37,86,87), but can persist for more 
than one year, especially for patients with chronic arthralgia (88,89). In case of CHIKV infections with 
neurological involvement, cerebrospinal fluid (CSF) can be tested for IgM antibodies (90,91). 
According to case reports, they would appear a little later than in serum (57); moreover, the higher 
the IgM titer in the serum, the higher it is in CSF (53).  
IgG antibodies are typically found as early as 6-7 days after illness onset, a few days after IgM 
appearance (37,87); like some IgM antibodies, they can directly neutralize CHIKV multiplication and 
can persist in immune individuals for many years (92). In the case of a strong and long-lasting IgM 
response, it seems that IgG seroconversion can occur late, with no IgG detected in some patients 90 
days after symptom onset (39). Among all four IgG isotypes, IgG3 antibodies dominate in the 
naturally-acquired IgG response, and they are mostly specific for the E2 protein (93,94). Their 
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appearance during the early convalescent phase has been associated with virus clearance, long-term 
clinical protection and better outcome (95). 
Cross-reactivity of CHIKV antibodies has been observed with members of Semliki Forest serocomplex, 
especially with viruses having a close genetic and evolutionary relationship (ONNV, MAYV, ross river 
virus-RRV) (96–98). It will be discussed more in detail in the paragraph 3.2.8. 
 
3.2.2. Choice of test 
After the period of viremia has ended, diagnosis may rely on virus detection in other fluids or tissues 
(see above) or on serological assays. A variety of laboratory diagnostic methods have been developed 
over time, including immunofluorescence tests (IFT), haemagglutination-inhibition assays (HIA), 
enzyme-linked immunosorbent assays (ELISA) and neutralization tests (NT). 
ELISAs are the most commonly used assays for detection of both IgG and IgM antibodies. ELISA and 
IFT, in contrast to HIA and NT, can make the distinction between IgM and IgG; this is useful because 
the detection of IgM, or detection of IgG seroconversion or a four-fold rise in antibody titers in paired 
specimens (collected during the acute and convalescent phases of the disease) are generally used as 
criteria to make a reliable diagnosis of infection.  
3.2.3. Commercial serological tests (IgM) 
A search for commercially available tests identified different kits dedicated to the detection of anti-
CHIKV IgM, most of which have been evaluated in clinical or EQA studies (99–105) (Supplementary 
data-Table 2 and table 3). Immunochromatographic rapid tests (CTK and SD Diagnostics) are an 
attractive diagnostic option, but their performances are characterized by  low sensitivity (99–
102,105). IFT by EUROIMMUN proved to be highly sensitive and specific (96,9% and 98,3% 
respectively) (103), although a variation in sensitivity was observed in two independent outbreaks 
caused by different strains of CHIKV, possibly  due to amino acid differences in the viral E1 and E2 
envelope proteins (102). Immuno-enzymatic tests represent the most common commercially 
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available assays, although performances in terms of sensitivity and specificity are quite diversified. 
According to Johnson et al. (99), who evaluated most of them, IgM ELISA by EUROIMMUN and InBios 
have the highest sensibility and sensitivity (although in a follow-up study EUROIMMUN ELISA was 
affected by cross-reaction, with detection of anti-ONNV IgM (100)). The Abcam ELISA also gave 
reliable results, although a considerable batch-to-batch variability was observed; ELISA assays by CTK, 
Genway, SD and IBL lacked sensitivity and are not recommended in their current format. 
 
3.2.4. Commercially available serological tests (IgG) 
Some of the commercially available tests for IgG detection have been evaluated (Supplementary 
data-Table 3 and table 4). IFT (immunofluorescent test) by EUROIMMUN showed high sensitivity and 
specificity (95,4% and 100%, respectively) (103). ELISA by EUROIMMUN and IBL proved to be specific 
(95% and 96%), but had lower sensitivity (88% and 52%); both detected anti-ONNV IgG, and the 
EUROIMMUN ELISA also anti-MAYV IgG (100).  
3.2.5. International Standard (IS) 
No IS for serological test is currently distributed.  
3.2.6. External Quality Assessment (EQA) 
Three EQAs (Table 5) were organised by ENIVD to investigate laboratories’ capacity for serological 
detection of CHIKV infections. Donoso-Mantke organised in 2007 an EQA analysis that included 24 
laboratories from 15 European countries (83). Of 18 participants that performed serologic assays, 14 
tested for both IgM and IgG and 4 tested only for IgG. Serology testing revealed greater differences 
amongst laboratories than molecular testing. Good performances were proved for 8 out of 14 
laboratories testing for both IgM and IgG, as well as for 3 out of 4 laboratories testing only for IgG; all 
the other laboratories lacked in sensitivity. No false-positive reactions from cross-reactivity with 
antibodies against viruses other than CHIKV were observed. 
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In 2007, 30 expert laboratories from 23 countries in Europe, the Middle East, Asia, Africa, North 
America and the Caribbean were involved in the second EQA on diagnostic serological proficiency 
(Niedrig et al. (106)). Only 6/30 obtained the highest score: for the others, a lack of sensitivity, 
especially for IgM, was observed. Most laboratories used in-house tests; IFT IgM/IgG by 
EUROIMMUN was the most common commercial assay. No significant variation in performance was 
observed when comparing the assay type (immunoenzymatic versus immunofluorescence assays) or 
origin (in-house versus commercial assays); a strong variability in diagnostic accuracy was reported 
among laboratories using the same commercial assay, probably due to improper handling of samples 
and/or assays. 
The most recent EQA for serological detection of CHIKV was organized in 2014 (Jacobsen et al, (69)) 
involving 56 laboratories from 40 countries in Europe, Asia, Africa, the Middle East, the Americas, the 
Caribbean and Oceania; 46 and 50 data sets were returned for anti-CHIKV IgG and IgM, respectively. 
A lack of sensitivity and, to a lesser extent, specificity, were more common for IgM detection than for 
IgG, with 1/50 and 20/46 laboratories achieving the highest score for IgM and IgG, respectively. The 
most widely used type of technology was a commercial IFT, followed by in-house ELISA, commercial 
ELISA and in-house IFT; other techniques such as virus neutralization test (VNT) and 
haemagglutination inhibition assays (HI) were rarely used.  Commercial IFT assays were less capable 
of detecting low IgM titres, but not with IgG in the same dilution series; in-house ELISAs proved to be 
more sensitive than commercial ELISAs, but less sensitive than IFT and VNT. 
 
3.2.7. Cryoglobulinaemia (IgM) 
Cryoglobulins are single or mixed immunoglobulins that undergo reversible precipitation at low 
temperatures. Cryoglobulinaemia refers to a condition with cryoglobulins in the serum; it has been 
described for several infectious diseases, particularly hepatitis C infection.  A high prevalence of 
CHIKV-mixed cryoglobulinaemia (MC) (with type II, II-III or III cryoglobulins) has been described by 
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Oliver et al. (107) in CHIKV-infected travellers coming back from the Western Indian Ocean. 
According to this study, CHIKV-MC can lead to misdiagnosis of the disease when ELISAs are 
performed on samples kept at 4°C: specific anti-CHIKV IgM could be trapped in the cryoprecipitate, 
causing unexpected seronegativity for patients with clinical suspicion of CHIKV infection. To 
circumvent the problem, it is suggested to manage blood samples as required for any cryoglobulin 
research: sampling and centrifugation at 37°C, decantation and serum pre-warming before the ELISA 
assays. 
 
3.2.8. Cross-reactivity 
Because of phylogenetic relationships among the three viruses, cross-reactivity, especially between 
anti-CHIKV and anti-ONNV antibodies, is a major concern when serological tests are performed to 
make a reliable diagnosis. Cross-reactivity between anti-ONNV and anti-CHIKV antibodies has been 
primarily investigated as MAYV had a distinct geographic distribution in the past; however, with the 
appearance of CHIKV in the Americas (108) and MAYV in the Caribbean (20), the antigenic 
relationship between the two viruses needs to be evaluated more carefully. 
CHIKV is closer phylogenetically to ONNV than to MAYV; this explains the substantial cross-reactivity 
observed for both IgM and IgG using ELISA and IFT (82,96,100,109). However, there are no 
documented studies evaluating the exact incidence of serologic cross-reactivity between the two 
viruses. Even in seroneutralization, it is difficult to differentiate antibodies against CHIKV and ONNV 
unless consistent differences in reciprocal cross-neutralization occur, which is not typical. 
CHIKV and MAYV are more distant phylogenetically, but cross-reactivity has been observed with both 
ELISA and IFT (96,100,110); presumably, it is less extensive than with ONNV, but no accurate 
estimation of cross-reactivity incidence between CHIKV and MAYV could be identified in the 
literature.                                                                                                                                                                                                                                               
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3.2.9. Cross-neutralization and cross-protection 
CHIKV-ONNV-MAYV: Cross-neutralization and cross-protection are important aspects to consider, 
because of implications for disease spread, as well as from the perspective of vaccine development. 
Despite this, few studies have been performed, suggesting that anti-CHIKV antibodies can neutralize 
and protect against MAYV and ONNV infections better than how anti-ONNV and anti-MAYV 
antibodies can do against CHIKV infection. 
One-way cross-neutralization has been demonstrated for CHIKV-ONNV, with anti-CHIKV immune 
serum inhibiting ONNV plaque formation, while antiserum to ONNV is less effective against CHIKV 
strains (111). Similar results were observed in studies showing that serum or monoclonal antibodies 
(mabs) derived from ONNV-infected animals or humans weakly neutralize CHIKV (112,113): 
Blackburn et al. observed that, using a immunofluorescent test (IFT), 86% of the mabs against CHIKV 
reacted with ONNV, whereas only 53% of the ONNV mabs reacted with CHIKV strain. A possible 
explanation could be that, during its evolution, ONNV has retained most of the CHIKV antigenic sites, 
whereas some of ONNV epitopes have undergone greater conformational change, so that mabs 
prepared against them neutralize weakly or not at all against CHIKV (113).  
The ability of anti-CHIKV antibodies to neutralize and protect against ONNV infection has been 
recently investigated in vivo: a recombinant CHIKV candidate vaccine was demonstrated to elicit a 
strong cross-neutralizing antibody response in a mouse model, conferring protection also against 
ONNV infection (114). 
As concerns cross-neutralization between CHIKV and MAYV, a plaque-neutralization test has showed 
that MAYV antiserum slightly neutralizes CHIKV, while no inhibition effect on MAYV has been caused 
by CHIKV antiserum (112).  
Considering overall findings about anti-CHIKV antibodies effect on MAYV and ONNV, they are 
diversified and need further assessment. Porterfield et al. (112) showed that CHIKV antiserum 
neutralizes efficiently ONNV but not MAYV. These results contrast with what observed by Fox et al. 
(115) using two murine mabs against epitopes on the B domain of the CHIKV E2 protein: in vitro, they 
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cross-neutralized MAYV more than ONNV; in a mouse model, they proved to be able to protect 
against MAYV infection, and to reduce disease caused by ONNV.   
 
4. O’nyong-nyong and Mayaro virus  
4.1. Molecular diagnosis 
4.1.1. Kinetics of viral load and dedicated biological sampling 
ONNV: Only few published studies have examined ONNV kinetics; similarly to CHIKV, ONNV viremia 
seems to last approximately one week or less (116).  
MAYV: Case reports suggest a very narrow window during which molecular assays can detect 
circulating virus. Halsey et al. (117) observed negative results in two samples collected beyond day 3 
of symptoms and tested by PCR; similarly, 4 days after the onset of illness Coimbra et al. could not 
detect viremia from two MAYV-case blood samples (118). However, an extended viremia (10 days) 
has been observed in an HIV-infected patient, possibly due to his immunocompromised status (119). 
For both ONNV and MAYV, molecular tests were performed only on sera collected at the acute stage 
of infection.  
4.1.2. Choice of test  
ONNV – MAYV: Suggestions about the choice of test for molecular diagnosis of infections are the 
same provided to detect CHIKV infection and have been discussed in the paragraph 3.1.2.   
 
4.1.3. In house real-time RT-PCR  
ONNV – MAYV: Few published studies have described PCR platforms for the detection of ONNV 
(66,120–122); they are listed in Table 6. As concerns MAYV, an alignment of 20 sequences available 
in GenBank, representing the main MAYV lineages, was made to assess primer sets developed in-
house by various laboratories. The results of this in silico analysis are presented in Table 7; as 
explained for CHIKV, a single mutation in the five 3’ terminal positions of a primer can significantly 
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compromise its detection capability, so mismatches concerning nucleotides in these positions are 
highlighted in the table. Most PCR systems use primers and probe showing one or more mismatches 
with MAYV strains. 
4.1.4. Commercial molecular tests 
ONNV – MAYV: They are not included as target in any commercial tests. 
4.1.5. International Standard (IS) 
ONNV – MAYV: No international standard for molecular detection of the two viruses has been 
developed. 
4.1.6. External Quality Assessment (EQA) 
ONNV – MAYV: No EQAs have ever been organised to evaluate laboratory’ capacity for ONNV and 
MAYV detection. 
4.2. Serological diagnosis 
4.2.1. Kinetics of immune response 
ONNV: Little is known about the kinetics of the antibody response to ONNV. IgM antibodies typically 
peak two weeks after the onset of illness and persist for about two months (62,116), although a few 
cases have been described with detectable IgM for 6 months or more (116). Information about anti-
ONNV IgG comes only from two case reports: a traveller returning from Kenya experienced IgG 
seroconversion 26 days after disease onset (123); a report from Chad described a peak in a patient’s 
IgG titre 68 days after the acute stage of illness (62). 
MAYV: Anti-MAYV antibody kinetics are also poorly documented. IgM typically appears three days 
after the onset of illness (124) and lasts for three months or more, but not beyond six months 
(117,124). In contrast, IgG may persist for years (124). In a case report, the absence of IgG 
seroconversion was reported in a patient 3 months after onset of illness, probably because the time 
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between disease onset and the last blood sampling in this patient was too short to allow Ig class 
switching (125). 
 
4.2.2. Choice of test 
ONNV-MAYV: Suggestions about the choice of test for serological diagnosis of infections are the 
same provided to detect CHIKV infection and have been discussed in the paragraph 3.2.2. 
 
4.2.3. Commercial serological tests 
ONNV: There is no commercial kit for IgM or IgG detection. 
MAYV: EUROIMMUN developed an anti-MAYV ELISA (IgM-IgG) but it has not been evaluated.  
 
4.2.4. International Standard (IS) 
ONNV-MAYV: No IS for serological tests is currently available. 
 
4.2.5. External Quality Assessment (EQA) 
ONNV-MAYV: No EQA has been organised to evaluate laboratory capacity for the serologic diagnosis 
of ONNV or MAYV infection. 
 
4.2.6. Cryoglobulinaemia 
ONNV-MAYV: The presence of cryoglobulins in sera from patients positive for CHIKV infection should 
have encouraged to assess it for ONNV and MAYV also. Actually, no study about cryoglobulinaemia in 
sera from patients positive for ONNV or MAYV has been performed.  
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4.2.7. Cross-reactivity, cross-neutralization and cross-protection 
These items have been discussed in the paragraph 3.2.8 and 3.2.9.  
 
5. Discussion 
The development, validation and evaluation of diagnostic tools are crucial steps to developing 
accurate diagnostic methods of alphavirus infections. A considerable amount of financial resources 
and efforts are necessary to implement virus and virus-specific antibody detection. This justifies why 
diagnostic tools ideally should be developed before outbreaks, in order to ensure a rapid response, 
and it’s valid especially for pathogens showing clear assumptions of large-scale dissemination. 
The recent occurrence of extensive CHIKV epidemics has necessitated improved documentation of 
infection and has impelled laboratories and companies to develop specific molecular and serological 
assays. However, it has also highlighted the need for improved capacity for diagnostic surveillance, 
especially when the co-circulation of closely related viruses increases the chance of misdiagnosis.  
ONNV and MAYV have been discussed in parallel with CHIKV because their similar clinical 
presentations, serological cross-reactivity and geographic areas of co-circulation are significant 
barriers to specific diagnosis. 
 
6. Knowledge gaps 
 
6.1. Chikungunya virus 
 
• Kinetics of viral load and dedicated biological sampling: different kinds of clinical samples have 
been used for the molecular detection of the virus. However, for some of them (i.e. urine and 
breast milk) the time window for detection of the viral genome remains unclear, with different 
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authors reporting contradictory results.  Comparative studies to assess body fluids are missing: 
they should be performed to better document kinetics of viral loads and to identify the most 
appropriate samples for diagnostic use at the different steps of the disease.  
• In-house real-time PCR protocols: several in-house real-time PCR protocols have been published, 
with different performances in the detection of the CHIKV lineages predicted from in silico 
analyses. An in vitro analytical evaluation would allow to better assess the adequacy of PCR 
systems to detect different lineages.  
• Commercial real-time PCR assays: a large number of commercial tests are available for molecular 
diagnosis. The performances of only one kit have been reported under the form of a scientific 
article. Kits datasheets commonly provide insufficient information regarding the lineage(s) 
detected and how the performances of the assay were evaluated. Lack of information about 
primers and probes used does not allow assessment of adequacy for covering existing genetic 
variability.  In the context of External Quality Assessments, some commercial tests are not clearly 
identified.    
• Molecular International Standards: development of IS is essential for harmonisation of results 
among different laboratories; however, the only IS available for molecular diagnosis has been 
prepared with one ECSA strain, despite the significant genetic diversity between CHIKV lineages. 
• Commercially available serological assays: a large number is available and several evaluations 
have been published; however, end-users would benefit from the guidance of a global and 
independent test evaluation. 
 
6.2. O’nyong-nyong and Mayaro virus 
 
• Kinetics of viral load and dedicated biological sampling: few cases are described in the literature 
and do not provide a clear picture of the kinetics of viremia. This could be problematic especially 
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for MAYV, which may have a shorter window of viremia compared to CHIKV and ONNV. To the 
best of our knowledge, no samples other than sera have been tested, so that kinetics of viral 
loads in different body fluids have never been described. 
• Kinetics of the immune response: it is only documented from a few case reports; accordingly, it is 
not clear when antibodies would appear and how long they would persist in sera. 
• In-house real-time PCR protocols: a few in-house real-time PCR protocols have been published 
for both pathogens. In silico analysis shows that most primers and probe sets have one or more 
mismatches with some MAYV evolutionary lineages. An in vitro analytical evaluation would allow 
to better assess the performances of the PCR systems and their adequacy to detect the different 
MAYV lineages.  
• Commercial molecular and serological tests: none is available for ONNV; one serological assay 
(IgM) is available for MAYV, but it has not been evaluated. 
• Molecular International Standards: none is available.  
• External Quality Assessments (EQAs): they have never been organized to evaluate laboratories’ 
capacity to diagnose ONNV and MAYV infection. 
 
6.3. All three viruses 
 
• Cryoglobulinaemia: false negative serological results due to cryoglobulinaemia have been 
reported for patients infected with CHIKV (only one study available). The presence and role of 
cryoglobulinaemia have not been investigated for ONNV and MAYV. 
• Cross reactivity and virus co-circulation: substantial cross-reactivity between anti-CHIKV and anti-
ONNV antibodies, as well as between anti-CHIKV and anti-MAYV has been reported, but poorly 
characterized. Differential diagnosis (CHIKV-ONNV and CHIKV-MAYV) in co-circulation areas is a 
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challenging task. Serological assays allowing differential identification of the infection by the 
different viruses are required.  
• Cross-neutralization and cross-protection: few studies have been performed, which limits the 
ability to assess cross-neutralization and/or cross-protection. 
 
7. Expert recommendations 
 
7.1. Chikungunya virus 
 
• In-house real-time PCR protocols: the numerous laboratory-developed protocols would benefit 
from a shared platform with in silico analysis of primers and probe sets; it could help to identify 
the most appropriate PCR for detection of circulating strains. A similar service has been 
previously proposed by the European Virus Archive website upon emergence of the CHIKV Asian 
genotype in the Caribbean. A host website governed by a non-commercial academic or public 
health organization, should be identified to implement this database and to contain results of 
laboratory comparative tests. After having defined mechanism of analysis and collection of 
results, this could be proposed as a model for other emerging viral diseases. 
• Commercially available real-time PCR tests (i): analytical evaluation and comparative studies of 
commercial molecular assays should be performed to assess both sensitivity and specificity. 
Results of External Quality Assessments should be made available with a clear identification of 
the commercial assays used. 
•  Commercially available real-time PCR tests (ii): to assess the adequacy of commercial tests for 
genomic diversity of CHIKV, companies should make publicly available detailed information 
about primers and probes sets and/or provide updated performance analysis of their kits for 
detection of existing and newly identified variants. 
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• Serological tests: to better assess laboratory capacity for serological diagnosis, reference panels 
should be constituted and tested using operational tests. This could help to evaluate 
performances of both commercial and in-house tests.  
• Commercially available serological tests: including commercial tests in EQAs and in comparative 
studies can help laboratories in their choice for the most reliable diagnostic assays. 
 
7.2. O’nyong-nyong and Mayaro virus 
 
• In general: both ONNV and MAYV require specific efforts for implementing clinical and 
epidemiological studies. 
• Viremia: viremia kinetics, as well as viral loads in different body fluids, should be better 
documented. 
• Immune response: the kinetics of the antiviral IgM and IgG response should be evaluated during 
the course of natural infection. 
• Commercial molecular and serological tests: they should be developed and evaluated through 
comparative studies. 
• International Standards (IS): they should be made available, taking into account the MAYV 
genetic heterogeneity. 
• External Quality Assessments (EQAs): they should be organized to assess laboratory capacity of 
detecting ONNV and MAYV with molecular and serological tools. 
 
7.3. All three viruses 
 
• Kinetics of viral load and dedicated biological sampling: a detailed analysis of the presence of the 
viruses in different body fluids over the course of infection should be performed and lead to a 
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rational standardization of the process of clinical sampling according to the clinical presentation 
and stage of the disease. 
• In-house real-time PCR protocols: the lack of information about assay performances could be 
filled by organizing comparative studies, with several laboratories testing reference panels by 
molecular methods; the evaluation should include other viruses at risk of cross-reactivity and 
different CHIKV and MAYV genotypes, in order to determine limit of detection (LOD) for each 
genotype. If necessary, new protocols for molecular diagnosis should be developed. 
• Genomic sequence database: experts recommend that a genomic reference database should be 
made available similar to those existing for other viruses (e.g. see the sites of the Virus Variation 
Resource (126) or the Virus Pathogen Resource (127). This database would allow to store 
available sequence data, together with gene and protein annotations and information about 
isolation hosts and sources.  
• International Standards (IS): it is highly recommended to develop IS for CHIKV Asian and West-
African lineages, as well as for MAYV and ONNV. 
• Cryoglobulinaemia: further studies should be implemented to confirm and better document the 
impact of cryoglobulinaemia in unexpected CHIKV seronegativity, as well as to extend 
investigations to ONNV and MAYV infections. 
• Co-circulation: viral co-circulation requires the development of molecular and serological 
multiplex tools to differentiate CHIKV from ONNV in Africa and from MAYV in Southern and 
Central America. 
• Cross-reactivity: multidirectional studies should be implemented to better define the exact 
extent of CHIKV cross-reactivity with ONNV and MAYV; this would be most probably required 
obtaining characterized samples for both naturally exposed humans and experimentally infected 
non-human primates. 
• Cross-neutralization and cross-protection: cross-neutralization and cross-protection studies 
between the three viruses should be implemented, including studies to identify potential ONNV- 
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and MAYV- specific monoclonal antibodies; as for cross-reactivity, samples from both naturally 
exposed humans and experimentally infected non-human primates should prove useful for this 
purpose. 
 
In summary, analysis of the currently available literature and consultation of experts indicate that 
inadequate diagnostics are currently available for ONNV and MAYV and, to a lesser degree, for 
CHIKV. Gaps in diagnostic tools and protocols allowing the identification of the etiological agent 
during the course of CHIKV, ONNV and MAYV infections have been identified for both diagnosis 
during the acute phase and for the long-term follow-up of patients, as well as for sero-
epidemiological studies.  
Diagnosis of the disease at the acute phase relies mostly on molecular detection of the virus genome. 
Molecular assays have been described for CHIKV, ONNV and MAYV but require further evaluation, 
standardized protocols and the availability of international standards representing the genetic 
diversity of the viruses. Alternatively, diagnosis can be provided by the detection of specific IgM, but 
the exact extent of cross-reactivity between the three viruses, the sensitivity of the assays, and the 
possible interfering role of cryoglobulinaemia require further investigation. Implementation of 
reference panels and EQAs for both molecular and serological assays is necessary. 
Regarding sero-epidemiological studies, there is no reported high throughput assay that enables the 
different viruses to be distinguished in areas of potential co-circulation. Even neutralization assays 
can lead to ambiguous interpretation. New specific tools and/or improved standardized protocols are 
needed to enable large-scale epidemiological studies of public health relevance to be performed. 
Regarding the long-term follow-up of patients infected by CHIKV (and potentially ONNV and MAYV) 
there is currently no biological marker of medical significance associated with disease progression 
and prognosis. This obviously requires a complete reassessment and specific investigation. 
Finally, when pathogens emerge or re-emerge, there is little time for development of diagnostics, 
which should be designed and validated in advance to ensure a rapid response. Considering the high 
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risk of future CHIKV, MAYV and ONNV outbreaks, it is highly recommended that a major investigation 
should be initiated to fill existing diagnostic gaps. 
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Fig. 1. Windows of detection of CHIKV genomes in different kinds of samples by molecular methods. The letters 
in brackets indicate the references. (a): (34,38,44); (b): (40,41); (c): (41); (d): (44); (e): (47,49); (f): (50); (g): (44); 
(h): (47); (i): (58); (j): (57); (k): (51).     
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 In house real-time PCR systems 
CHIKV WA 
(nb seq=10) 
CHIKV ECSA 
(nb seq=10) 
CHIKV IOL 
(nb seq=10) 
CHIKV 
ASIAN (nb 
seq=10) 
CHIKV 
ASIAN/AME
RICAN (nb 
seq=10) 
Target(s) Reference Technique 
Amplicon 
size (bp) 
  
  
Mismatch positions in primers and probe; the 3' terminal position 
corresponds to position 1; mismatches in the five 3' terminal 
nucleotides are indicated in red and bold; (nb of CHIKV sequences with 
mismatch in the specific lineage considered) 
NSP2 
Waggoner 
et al. (64) 
Hydrolysis 
probe 
96 
FW primer  
5'-3' 
CATCTGCACYC
AAGTGTACCA 
Pos 9: A>G 
(1) 
        
RV primer  
5'-3' 
GCGCATTTTGC
CTTCGTAATG 
    
Pos 13: T>C 
(1) 
    
Probe  
GCGGTGTACA
CTGCCTGTGAC
YGC 
          
E3 
Cecilia et 
al. (65) 
Hydrolysis 
probe 
64 
FW primer  
5'-3' 
CGAAAARGAR
CCGGAGRAA 
Pos 1: A>C 
(10) 
Pos 2: A>G 
(10) 
Pos 4: G>A 
(10) 
Pos 7: G>A 
(2) 
Pos 14: A>G 
(2) 
Pos 19: C>T 
(2) 
      
RV primer  
5'-3' 
GATAGTACCCR
GGKCTCATGAC
GTT 
Pos 6: G>C 
(10) 
Pos 18: C>T 
(10) 
Pos 24: A>G 
(10) 
  
Pos 4: C>T 
(1) 
Pos 3: G>A 
(3) 
Pos 3: G>A 
(10) 
Probe  
CCCTRCGCATG
CTTGA 
C>T (10)     C>T (3) C>T (10) 
E1 
Smith et 
al. (66) 
Hydrolysis 
probe 
253 
FW primer  
5'-3' 
CAGTGATCCCG
AACACGGTG 
          
RV primer  
5'-3' 
CCACATAAATG
GGTAGACGCC 
Pos 3: G>T 
(10) 
    
Pos 9: G>A 
(1) 
Pos 15: A>G 
(10) 
Pos 15: A>G 
(10) 
Probe  
CCGTCATCCCG
TCTCCGTACGT
GAA 
C>T (10) 
G>C (9) 
G>T (1) 
T>C (10) 
C>T (3)   
C>T (3) 
T>C (1) 
C>T (10) 
NSP1 
Smith et 
al. (66) 
Hydrolysis 
probe 
74 
FW primer  
5'-3' 
TTTGTGATCAA
ATGACCGGCAT
C 
Pos 1: C>T 
(9) 
Pos 4: C>T 
(10) 
Pos 7: C>A 
(10) 
        
RV primer  
5'-3' 
TCAGCCCCACC
AACAGCTTC 
Pos 8: A>G 
(10) 
Pos 16: C>T 
(10) 
Pos 17: G>A 
(1) 
Pos 8: A>G 
(10) 
      
Probe  
TTGCTACAGAA
GTCAC 
T>C (10) 
A>G (10) 
A>G (10) 
C>T (10) 
A>G (1)       
NSP2  Smith (66) 
Hydrolysis 
probe 
70 
FW primer  
5'-3' 
CCGAAAGGAA
ACTTCAAAGCA
ACT 
Pos 1: T>A 
(9) 
Pos 10: C>T 
(10) 
Pos 13: C>T 
(10) 
Pos 10: C>T 
(10) 
  
Pos 7: A>G 
(7) 
Pos 7: A>G 
(10) 
RV primer  
5'-3' 
CAGATGCCCG
CCATTATTGAT
G 
Pos 2: T>A 
(10) 
Pos 17: G>A 
(10) 
    
Pos 5: T>C 
(10) 
Pos 21: A>G 
(1) 
Pos 5: T>C 
(10) 
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Probe  
GGGAGGTGGA
GCATG 
G>A (10) 
G>A (10) 
    T>C (10) T>C (10) 
5'UTR  
Smith et 
al. (66) 
Hydrolysis 
probe 
98 
FW primer  
5'-3' 
ACACACGTAGC
CTACCAGTTTC 
  
Pos 5: G>T 
(1) 
Pos 6: A>G 
(1) 
Pos 11: C>T 
(1) 
Pos 11: C>T 
(1) 
Pos 16: G>A 
(1) 
Pos 8: C>T 
(1) 
Pos 16: G>A 
(1) 
Pos 8: C>T 
(1) 
RV primer  
5'-3' 
GCTGTCAGCGT
CTATGTCCAC 
Pos 15: A>G 
(10) 
    
Pos 6: G>A 
(7) 
Pos 6: G>A 
(7) 
Probe  
TA-
CTGCTCTACTC
TG 
  - >A (1)        
NSP1 
Panning et 
al. (38) 
Hydrolysis 
probe 
82 
FW primer  
5'-3' 
TGATCCCGACT
CAACCATCCT 
    
Pos 18: T>C 
(10) 
    
RV primer  
5'-3' 
GGCAAACGCA
GTGGTACTTCC
T 
Pos 9: G>A 
(2) 
Pos 18: A>G 
(4) 
Pos 18: A>G 
(4) 
    
Probe  
GCCAGCAAGG
AGGATGATGT
CGGA 
  G>A (2)     G>A (1) 
NSP1 
Lanciotti 
et al. (34) 
Hydrolysis 
probe 
87 
FW primer  
5'-3' 
AAAGGGCAAA
CTCAGCTTCAC 
Pos 12: A>G 
(10) 
Pos 15: C>G 
(10) 
Pos 18: G>A 
(10) 
Pos 12: A>G 
(6) 
  
Pos 9: C>T 
(9) 
Pos 12: A>G 
(9) 
Pos 9: C>T 
(9) 
Pos 12: A>G 
(9) 
RV primer  
5'-3' 
GCCTGGGCTCA
TCGTTATTC 
Pos 11: C>A 
(10) 
Pos 17: T>C 
(10) 
Pos 13: C>T 
(1) 
Pos 14: G>A 
(1) 
  
Pos 2: T>C 
(1) 
Pos 17: T>C 
(1) 
  
Probe  
CGCTGTGATAC
AGTGGTTTCGT
GTG 
  T>G (10)   T>C (9)   
NSP4 
Lanciotti 
et al. (34) 
Hydrolysis 
probe 
125 
FW primer  
5'-3' 
TCACTCCCTGT
TGGACTTGATA
GA 
Pos 20: T>C 
(10) 
Pos 21: C>T 
(10) 
Pos 14: T>C 
(2) 
Pos 14: T>C 
(10) 
Pos 8: T>C 
(3) 
Pos 17: C>T 
(2) 
Pos 8: T>C 
(10) 
Pos 17: C>T 
(10) 
RV primer  
5'-3' 
TTGACGAACA
GAGTTAGGAA
CATACC 
Pos 9: G>A 
(3) 
Pos 10: G>A 
(1) 
Pos 15: A>G 
(10) 
        
Probe  
AGGTACGCGC
TTCAAGTTCGG
CG 
A>G (10) 
T>C (10) 
G>T (1) 
C>T (10)     
C>T (10) 
C>T (1)   C>T (1)   
E1 
Edwards 
et al. (67) 
Hydrolysis 
probe 
126 
FW primer  
5'-3' 
TCGACGCGCCC
TCTTTAA 
Pos 4: T>G 
(10) 
Pos 11: G>A 
(10) 
Pos 14: C>T 
(10) 
Pos 5: T>C 
(1) 
Pos 14: C>A 
(1) 
  
Pos 8: C>A 
(10) 
Pos 8: C>A 
(10) 
RV primer  
5'-3' 
ATCGAATGCAC
CGCACACT 
          
Probe  
ACCAGCCTGCA
CCCATTCCTCA
GAC 
C>T (10) 
T>C (1) 
A>C (10) 
C>T (2)   
C>T (4) 
A>G (1) 
C>T (10) 
E1 
Pastorino 
et al. (68) 
Hydrolysis 
probe 
208 
FW primer  
5'-3' 
AAGCTYCGCGT
CCTTTACCAAG 
  
Pos 5: C>T 
(1) 
      
RV primer  
5'-3' 
CCAAATTGTCC
YGGTCTTCCT 
      
Pos 16: T>C 
(1) 
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Probe  
CCAATGTCYTC
MGCCTGGACA
CCTTT 
  C>G (1)       
 
Table 1. Ten sequences were selected for each lineage (CHIKV WA, GenBank accession numbers: HM045815, 
HM045818, AY726732, HM045817, HM045785, HM045798, HM045786, HM045807, HM045819, HM045820; 
CHIKV ECSA: AF369024, AF490259, KJ679577, KP164570, KY704947, HM045822, HM045806, HM045795, 
HM045792; JQ067624; CHIKV IOL:  GQ428211, FJ807896, FJ000062, FJ807899, GQ428212, EF027136, 
EU564334, EF012359, HQ456254, MG664850; CHIKV Asian FJ807897, HM045791, HM045787, HM045789, 
HM045814, HM045810, HM045788, EF027140, EU703759, KT308159; CHIKV Asian/American: KR559497, 
KR559496, KR559473, KR559492, KJ451624, KR046227, KR046231, LN898098, LN898093, KR559493). Mismatch 
positions between this reference sequence panel and the primers and probes are indicated in the table; 
mismatches concerning the five 3’ terminal nucleotides of a primer are indicated in red and bold characters. In 
probes, 1 or 2 mutations generally do not compromise the hybridization potential, but this also depends on the 
length of the probe and its G+C content.   
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Year Reference Participants Study coordinator Objectives 
Other viruses 
tested in the 
panels 
Results of 
molecular 
assessment 
2007 
Donoso-
Mantke et al. 
(83) 
Total: 24 labs from 15 
European countries // 
20 labs for CHIKV PCR 
European Network for 
Diagnostics of Imported 
Viral Diseases (ENIVD) 
Assessing quality for 
CHIKV molecular and 
serological diagnostics 
- 
16/20 labs showed 
sufficient 
sensitivity and 
specificity 
2007 
Panning et al. 
(84) 
Total: 31 labs from 
Europe, Asia, Africa, 
South America 
European Network for 
Diagnostics of Imported 
Viral Diseases (ENIVD) 
Coordinated 
Implementation of 
CHIKV RT-PCR 
- 
14/31 labs met 
proficiency criteria 
2014 
Jacobsen et al. 
(69) 
Total: 56 labs from 40 
countries (Europe, Asia, 
Africa, Middle East, 
Americas, Caribbean, 
Oceania) 
European Network for 
Diagnostics of Imported 
Viral Diseases (ENIVD) 
Assessing quality for 
CHIKV molecular and 
serological diagnostics 
SINV, ONNV, 
DENV 
23/60 data sets 
classified as 
“optimal”, 7/60 
“acceptable”, 
30/60 “need for 
improvement” 
2015 Soho et al. (85) 
Total: 24 labs from 22 
countries and areas 
(South-East Asia, 
Western Pacific 
Regions) // 20 labs for 
CHIKV PCR 
- 
Assessing quality for 
CHIKV molecular 
diagnostic and for 
DENV molecular and 
serological diagnostics 
DENV 
19/20 labs reached 
the highest score 
 
Table 2. EQAs for molecular detection of CHIKV RNA. 
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Kit Company Method Performance (ref) 
Human Anti-CHIKV IgM 
ELISA Kit 
Abcam IgM ELISA 
Lot-to-lot variation: good concordance with CDC results vs low 
sensitivity (99) 
CHIK IgM ELISA Test CE 
CTK Biotech 
IgM ELISA CDC: Low sensitivity (99) 
Chikungunya IgM Combo 
Rapid Test CE 
IgM-rapid 
test 
CDC: Low sensitivity (99–102) 
Anti CHIKV IFT 
EUROIMMUN 
 
IFT 
CDC: High accuracy and reproducibility; Good sensitivity and specificity; 
Variation in sensitivity for Ab against different CHIKV strains 
(99,102,103) 
Anti-CHIKV ELISA (IgM) IgM ELISA 
CDC: High accuracy and reproducibility; Cross-reactivity with anti-ONNV 
Abs; High sensitivity; False neg and false pos results (99,100,104) 
Chikungunya IgM µ-
capture ELISA 
GenWay IgM ELISA CDC: Low sensitivity (99) 
Chikungunya IgM µ-
capture ELISA 
IBL International IgM ELISA 
Cross reactivity with anti-ONNV Abs; False neg and false pos results 
(100) 
CHIKjj Detect™IgM ELISA 
Kit 
InBios IgM ELISA CDC: High accuracy and reproducibility; High sensitivity (99,104) 
SD Chikungunya IgM ELISA 
SD Standard 
Diagnostics 
IgM ELISA CDC: Low sensitivity (99,105) 
SD BIOLINE Chikungunya 
IgM 
IgM - rapid 
test 
CDC: Low sensitivity (99–101,105) 
 
Table 3. Performances of commercial tests for the detection of anti-CHIKV IgM antibodies, according to 
published evaluations. 
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Kit Company Method Performance (ref) 
Anti CHIKV IFT 
EUROIMMUN 
IFT 
Good sensitivity and specificity; Variation in sensitivity for Ab against different 
CHIKV strains (102,103) 
Anti-CHIKV ELISA (IgG) 
IgG 
ELISA 
Quite good sensitivity and specificity; Cross-reactivity with anti-ONNV and anti-
MAYV Abs; False neg and false pos results (100) 
CHIKjj Detect™IgG 
ELISA Kit 
InBios 
IgG 
ELISA 
Quite good sensitivity and specificity; Cross-reactivity with anti-ONNV Abs; False 
neg and false pos results (100) 
 
Table 4. Performances of commercial tests for detection of anti-CHIKV IgG, according to published evaluations. 
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Year Reference Participants Study coordinator Objectives 
Other viruses 
tested in the 
panels 
Results of serological 
assessment 
2007 
Donoso-
Mantke et al. 
(83) 
Total: 24 labs from 15 
European countries // 
18 labs for CHIKV 
serology 
European Network for 
Diagnostics of Imported 
Viral Diseases (ENIVD) 
Assessing quality for 
CHIKV molecular and 
serological diagnostics 
- 
8/14 labs showed 
good results for both 
IgM and IgG 
2007 
Niedrig et al. 
(106) 
Total: 30 labs from 23 
countries (Europe, 
Middle East, Asia, 
Africa, North America, 
Caribbean) 
European Network for 
Diagnostics of Imported 
Viral Diseases (ENIVD) 
Assessing quality for 
CHIKV serological 
diagnostics 
DENV, WNV 
6/30 labs with 100% 
correct results, 13/30 
labs with  ≥ 85% 
correct results, 11/30 
labs with ≤ 75% 
correct results 
2014 
Jacobsen et al. 
(69) 
Total: 56 labs from 40 
countries (Europe, Asia, 
Africa, Middle East, 
Americas, Caribbean, 
Oceania) 
European Network for 
Diagnostics of Imported 
Viral Diseases (ENIVD) 
Assessing quality for 
CHIKV molecular and 
serological diagnostics 
RRV, WNV, 
DENV 
IgM: 1/50 dataset 
classified as “optimal”, 
9/50 “acceptable”, 
40/50 “need for 
improvement”. 
IgG: 20/46 “optimal”, 
2/46 “acceptable”, 
24/46 “need for 
improvement” 
 
Table 5. EQAs for serological detection of CHIKV. 
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Year Reference Method Target 
2017 Waggoner et al. (120) 
Monoplex real time RT-
PCR 
5'UTR-nsP1 
2016 Liu et al. (121) 
Real-time PCR-based 
TaqMan array card 
(TAC) (15 viruses) 
E1 
2013 
Saxton Shaw et al. 
(122) 
Monoplex real time RT-
PCR 
E1 
2009 Smith et al. (66) 
Monoplex real time RT-
PCR 
E1 
nsP1 
nsP2 
Multiplex (OONV-
CHIKV) real time RT-
PCR 
5'UTR-nsP1 
 
Table 6. Published reports of RT-PCR systems for the detection of ONNV, in decreasing order of the year of 
publication.   
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 In house real-time PCR systems 
MAYV D (nb 
seq=10) 
MAYV N (nb 
seq=1) 
MAYV L (nb 
seq=9) 
Target(s) Reference Technique 
Amplicon 
size (bp) 
  
  
Mismatch positions in primers and probe; the 3' 
terminal position corresponds to position 1; 
mismatches in the five 3' terminal nucleotides are 
indicated in red and bold; (nb of CHIKV sequences 
with mismatch in the specific lineage considered) 
5'UTR-
nsP1 
Waggoner 
et al. (128) 
Hydrolysis 
probe 
109 
FW primer 
5'-3' 
AAGCTCTTCC
TCTGCATTGC 
Pos 14: T>A (1)     
RV primer 
5'-3' 
TGCTGGAAAC
YGCTCTYTGTA  
      
Probe  
GCCGAGAGCC
CGTTTTTAAA
ATCAC 
    T>C (3) 
nsP1 
Naveca et 
al. (129) 
Hydrolysis 
probe 
59 
FW primer 
5'-3' 
CACGGACMTT
TTGCCTTCA 
      
RV primer 
5'-3' 
AGACTGCCAC
CTCTGCTKGA
G 
Pos 2: A>G (1) 
Pos 8: T>1 (1) 
Pos 17: T>C (2) 
Pos 11: C>T (1) Pos 17: T>C (1) 
Probe  
ACAGATCAGA
CATGCAGG 
      
E1 
Llagonne-
Barets et 
al. (130) 
SYBR 
green 
165 
FW primer 
5'-3' 
TTCCRAAYCA
AGTGGGATTC 
      
RV primer 
5'-3' 
CACTTTACGT
AYGGKGATGG 
Pos 3: T>C (1) Pos 9: Y>A (1)   
Probe  NA       
nsP1 
Friedrich-
Jänicke et 
al. (131)  
Hydrolysis 
probe 
95 
FW primer 
5'-3' 
CCTTCACACA
GATCAGAC 
      
RV primer 
5'-3' 
GCCTGGAAGT
ACAAAGAA 
      
Probe  
GGTGGCAGTC
TATCAGGATG
TCTATG 
A>G (2) 
G>A (5) 
C>T (2) 
G>A (1) 
A>G (1) 
G>A (1)  
E2 
Long et al. 
(30) 
Hydrolysis 
probe 
127 
FW primer 
5'-3' 
CAAATGTCCA
CCAGGCGAA
G 
Pos 8: A>G (1)   
Pos 1: G>C (2) 
Pos 8: A>T (3), 
A>C (5) 
Pos 13: T>C (4) 
RV primer 
5'-3' 
GTGGTCGCAC
AGTGAATCTT
TC 
Pos 12: A>C (4) 
Pos 15: C>T (1) 
Pos 9: G>A (1) 
Pos 12: A>C (9) 
Pos 21: T>C (8) 
Probe  
GACCTGTCGG
ATAGCCTACC
ACCAT 
C>T (1) C>T (1) 
C>T (6) 
T>C (9) 
A>T (5) 
 
 
Table 7. We selected ten sequences for MAYV lineage D (GenBank accession numbers: KP842806, KP842795, 
KM400591, KJ013266, DQ001069, KP842807, KP842813, KP842800, KP842802, KP842809), one for MAYV 
lineage N (GenBank accession number: KP842812), nine for MAYV lineage L (GenBank accession numbers: 
KP842819, KP842820, KP842818, KT818520, KX496990, AF237947, NC_003417, KY618133, KY985361). 
Mismatch positions between this reference sequence panel and the primers and probes are indicated in the 
table; mismatches concerning the five 3’ terminal nucleotides of a primer are indicated in red and bold 
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characters. In probes, 1 or 2 mutations do generally not compromise the hybridization potential but this also 
depends on the length of the probe and its G+C content. D: dispersed; L: limited; N: new. 
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• Chikungunya, O’nyong-nyong and Mayaro virus represent emerging global health threats. 
• Similar clinical presentations and geographic areas of co-circulation are significant barriers to specific 
diagnosis.  
• Available molecular tests require further evaluation, standardized protocols and availability of 
International Standards. 
• Low sensitivity of the assays and cross-reactivity may affect the correct identification of antibodies by 
serological methods.   
• Experts recommend that a major effort should be done to implement available diagnostic tools.  
  
